Specifically, we focused on the expression of androgen receptor (AR) and heat shock protein 27 (HSP27) through immunostaining, as the AR–HSP27 axis has emerged as a novel therapeutic target for GBM, supported by evidence of sex-based differences in GBM progression. Here, AR is linked to glioblastoma.